|
Verici Dx PLC - Tennessee-based developer of clinical diagnostics for organ transplants - Plans to raise at least £10.0 million from the sale of 28.6 million new shares at 35 pence each. The fundraise is being run on Friday as an accelerated bookbuild by Singer Capital Markets. Verici DX says the funds will be used to accelerate the commercialisation of its two lead products, Clarava and Tuteva, and to continue the development of third product Protega. The results of the fundraise will be announced later Friday.
Current stock price: 36.10p, down 3.7% on Friday
12-month change: down 50%
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
